The Australian experience with switching to extended half‐life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation-Reference-Cited by-同舟云学术

The Australian experience with switching to extended half‐life factor VIII and IX concentrates: On behalf of the Australian Haemophilia Centre Directors' Organisation

Published:2020-04-03 Issue:3 Volume:26 Page:529-535
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Brennan Yvonne¹²^ORCID,Parikh Sumit¹,McRae Simon¹³,Tran Huyen¹⁴⁵

Affiliation:

1. Australian Haemophilia Centre Directors Organisation (AHCDO) Melbourne Vic. Australia

2. Department of Haematology Westmead Hospital Sydney NSW Australia

3. Department of Haematology South Australia Pathology Royal Adelaide Hospital Adelaide SA Australia

4. Ronald Sawyers Haemophilia Centre The Alfred Hospital Melbourne Vic. Australia

5. Australian Centre for Blood Diseases Monash University Melbourne Vic. Australia

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13970

Reference13 articles.

1. Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B

2. Real‐life experience in switching to new extended half‐life products at European haemophilia centres

3. Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP

4. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B

5. The impact of extended half-life versus conventional factor product on hemophilia caregiver burden

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of joint health in patients receiving prophylaxis for haemophilia A: a cross-sectional survey in five European countries;BMJ Open;2024-09

2. Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany;Research and Practice in Thrombosis and Haemostasis;2024-07

3. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis;Orphanet Journal of Rare Diseases;2024-03-26

4. Recombinant factor IX Fc for the treatment of hemophilia B;European Journal of Haematology;2024-02-18

5. Real-world analysis of the PK-guided switch from standard half-life factor VIII to efmoroctocog alfa;Thrombosis Research;2024-01